1887

Chapter 51 : The Future of Pathology and Laboratory Medicine: Political, Social, Economic, and Regulatory Impacts

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

The Future of Pathology and Laboratory Medicine: Political, Social, Economic, and Regulatory Impacts, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817282/9781555817275_Chap51-1.gif /docserver/preview/fulltext/10.1128/9781555817282/9781555817275_Chap51-2.gif

Abstract:

This chapter discusses the major features of the current healthcare environment. It describes the current regulations affecting laboratory practice. The chapter explains future regulations and political and economic events impacting pathology and laboratory practice. A high level of volatility and uncertainty, reflecting the political, economic, and social instability of our current environment, characterizes healthcare in the United States in the second decade of the 21st century. Funding and support for healthcare are diminishing, and the economic future of healthcare is hostage to some identifiable trends and concerns that include: a growing federal deficit and concerns about the future sustainability of Medicare and Medicaid; and a healthcare insurance and delivery system plagued by problems of access, quality, and safety. The “four horsemen” of federal laws and regulations that are particularly pertinent to pathology and laboratory medicine services are CLIA ’88, HIPAA, the Occupational Safety and Health Administration (OSHA) standards for occupational exposure to blood-borne pathogens, and the so-called Stark regulations that prohibit self-referral by healthcare providers. The increasing research and clinical demands for validated biospecimens can be expected to lead to significant growth in the number and size of biorepositories. Two other areas of concern to research and clinical laboratory practice are restrictive patents and excessive restraints on the use of human tissue and data for research and clinical purposes.

Citation: Bachner P. 2014. The Future of Pathology and Laboratory Medicine: Political, Social, Economic, and Regulatory Impacts, p 897-906. In Garcia L (ed), Clinical Laboratory Management, Second Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817282.ch51

Key Concept Ranking

Hepatitis B virus
0.645592
Influenza A virus
0.4506803
0.645592
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817282.chap51
1. Bachner, P.,, and W. B. Hamlin. 1993. Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988. Part I. Clin. Lab. Med. 13:739752. [PubMed]
2. Bachner, P.,, and W. B. Hamlin. 1993. Federal regulation of clinical laboratories and the Clinical Laboratory Improvement Amendments of 1988. Part II. Clin. Lab. Med. 13:987994. [PubMed]
3. Berwick, D. M.,, and L. L. Leape. 1999. Reducing errors in medicine. BMJ 319:136137. [PubMed]
4. Bierig, J. R. 2002. Liability and payment issues in the selection of pathology assays. Arch. Pathol. Lab. Med. 126:652657. [PubMed][CrossRef]
5. Brennan, T. A.,, A. Gawande,, E. Thomas,, and D. S. Studdert. 2005. Accidental deaths, saved lives, and improved quality. N. Engl. J. Med. 353:14051409. [PubMed][CrossRef]
6. Campbell, E. G. 2009. The future of research funding in academic medicine. N. Engl. J. Med. 360:14821483. [PubMed][CrossRef]
7. Duncan, H. 2008. An update on the Clinical Laboratory Improvement Amendments of 1988. Lab. Med. 39:6972.
8. Evans, J. P.,, and J. S. Berg. 2011. Next-generation DNA sequencing, regulation, and the limits of paternalism. JAMA 306:23762377. [PubMed][CrossRef]
9. Fung, C. H.,, L. Lim,, C. Mattke,, and P. G. Shekelle. 2008. Systematic review: the evidence that publishing patient care performance data improves quality of care. Ann. Intern. Med. 148:111123. [PubMed]
10. Giardina, T. D.,, and H. Singh. 2011. Should patients get direct access to their laboratory test results? JAMA 306:25022503. [PubMed][CrossRef]
11. Hudson, K. L. 2011. Genomics, health care, and society. N. Engl. J. Med. 365:10331041. [PubMed][CrossRef]
12. Iglehart, J. 2011. The uncertain future of Medicare and graduate medical education. N. Engl. J. Med. 365:13401345. [PubMed][CrossRef]
13.Institute of Medicine. 1999. To Err Is Human: Building a Safer Health Care System. National Academy Press, Washington, DC.
14. Kundera, M. 2002. The great return. The New Yorker. May 20.
15. Leape, L. L.,, and D. M. Berwick. 2005. Five years after To Err is Human. JAMA 293:23842390. [PubMed][CrossRef]
16. Leape, L. L.,, D. M. Berwick,, and D. W. Bates. 2002. What practices will most improve safety? Evidence-based medicine meets patient safety. JAMA 288:501507. [PubMed]
17. Mitchell, J. M. 2012. Urologists' self-referral for pathology of biopsy specimens linked to increased use and lower prostate cancer detection. Health Affairs 31:741749. [PubMed][CrossRef]
18. Spackman, K. 2002. SNOMED CT unlocks the power of clinical data for pathologists. Lab. Med. 33(3):14.
19. Wachter, R. M.,, N. E. Foster,, and R. A. Dudley. 2008. Medicare's decision to withhold payment for hospital errors. Jt. Comm. J. Qual. Patient Saf. 34:116123. [PubMed]
20. Wilson, M. L. 2002. Education and training: practice makes perfect. Am. J. Clin. Pathol. 118:167169. [PubMed][CrossRef]
21. Yost, J. 2012. CLIA update: what's on the agenda for 2012? Natl. Intelligence Rep. 12(6):47.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error